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Apoptotic cell death was induced in human lung cancer DMS114 cells by treatment with β-hydroxyisovalerylshikonin (β-HIVS), an ATP-
noncompetitive inhibitor of protein tyrosine kinases. Changes in phosphoprotein profiles were analyzed by two-dimensional-polyacrylamide gel
electrophoresis (2D-PAGE) after the cells were treated with β-HIVS. One spot on the 2D gel showed a marked decrease in intensity and the
corresponding protein was identified by mass spectrometry as dUTP nucleotidohydrolase (dUTPase). The β-HIVS-induced decrease of dUTPase
in the phosphoprotein fraction of DMS114 cells was confirmed using immunoblotting. Treatment of the cells with β-HIVS-induced rapid
reduction of dUTPase activity. An antioxidant N-acetyl-cysteine inhibited both the reduction of phosphorylated dUTPase and the induction of
apoptosis by β-HIVS treatment of DMS114 cells. Introduction of siRNA directed against dUTPase mRNA into DMS114 cells enhanced the
susceptibility of β-HIVS-induced apoptosis. Treatment of DMS114 cells with β-HIVS and 5-fluorouracil, a specific inhibitor of thymidylate
synthase used as a chemotherapeutic drug, revealed the synergistic effects of these drugs on the inhibition of cell growth. These results suggest that
dUTPase activity is one of the crucial factors involved in apoptotic cell death in lung cancer cells.
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Lung cancer is one of the leading causes of death in developed
countries and the number of patients has been growing in Japan
[1,2]. Metastasis and drug resistance are the major causes of
mortality in lung cancer, and the therapeutic results await further
improvement. Induction of apoptotic cell death specifically in
cancer cells would be an ideal way to combat tumors, because
apoptotic cell death does not induce an inflammatory response.
We have searched for various agents that induce apoptotic cell
death preferentially in cancer cells. Geranylgeraniol induced
apoptosis in U937 leukemia cells through enhanced release of
cytochrome c from the mitochondria [3]. Vitamin K2 was found
to be an active apoptosis inducer on ovarian cancer cells [4].
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rently used for several tumors including lung cancer. 5-FU is an
inhibitor of thymidylate synthetase, which catalyzes the con-
version of dUMP to thymidylate, which is required for the
synthesis of DNA. One of the enzymes that provides dUMP,
the substrate of thymidylate synthase, is dUTP nucleotidohy-
drolase (dUTPase). dUTPase is a ubiquitous enzyme that hy-
drolyzes dUTP to yield dUMP and pyrophosphate. Recent
studies have demonstrated that inhibition of thymidylate syn-
thase causes accumulation of dUTP, which leads to misincor-
poration of uracil into DNA and results in lethal damage to
DNA [5]. dUTPase is a major regulator of the size of the dUTP
pool and it protects cells from DNA damage by limiting the
accumulation of dUTP. Thus, activation of the expression of
the gene for dUTPase results in resistance to inhibitors of
thymidylate synthase, such as 5-FU [6,7], fluorodeoxyuridine
[8], and ZD9331 [9].
We previously reported that β-hydroxyisovalerylshikonin
(β-HIVS), which is isolated from the roots of the traditional
oriental medicinal herb Lithospermum radix, can inhibit the
growth of various lines of human cancer cells at concentrations
between 10−8 and 10−6 M [10]. Among the cancer cells
examined, β-HIVS was able to induce cell death the most
efficiently in DMS114 and NCI-H522 lung cancer cells [11]. It
is interesting that β-HIVS is an ATP-noncompetitive inhibitor
of tyrosine kinases such as v-Src and EGFR [11]. Indeed β-
HIVS induces apoptosis in DMS114 cells via a protein tyrosine
kinase (PTK)-dependent pathway [12].
It is well-known that protein phosphorylation is the major
signaling machinery in various cellular phenomena, such as cell
cycle, cellular locomotion, and apoptosis. Several protein
kinases are reported to be involved in the regulation of
apoptosis in cancer cells [13–15]. Many of the studies,
including our previous one, utilize inhibitors of protein kinases
to show the potential involvement of certain protein phosphor-
ylation in apoptosis, however such an approach might not be
suitable for elucidating the downstream mechanisms that induce
final events. In the present study, we used another strategy to
clarify details of the mechanism in induction of apoptosis in
cancer cells by β-HIVS. Since most cell-death and cell-
proliferation signals are transmitted via phosphorylation and
dephosphorylation of proteins, we focused on changes in the
phosphorylation of proteins during induction of apoptosis in
cancer cells by β-HIVS. Phosphoproteins in DMS114 cells
were fractionated using a phosphoprotein-purification column
and analyzed these phosphoproteins by two-dimensional-
polyacrylamide gel electrophoresis (2D-PAGE). We found
that the intensity of one spot on the 2D gel decreased
significantly after treatment of cells with β-HIVS and we
identified the corresponding protein by mass spectrometry as
dUTPase. Ladner et al. found both mitochondrial and nuclear
isoforms of dUTPase in human cells [16,17]. Ladner et al.
indicated that the nuclear isoform of dUTPase is a phospho-
protein and Ser11 is the only phosphorylated site in vivo [18].
They also demonstrated that neither the enzymatic activity nor
intracellular localization of dUTPase is affected by the
phosphorylation [18,19]. Since β-HIVS is a specific inhibitorof tyrosine kinase, its direct effect on dUTPase is not expected
and its effect may be transmitted through signaling cascade.
2. Materials and methods
2.1. Cell culture and reagents
We cultured DMS114 human small lung carcinoma cells in RPMI 1640
medium (GIBCO, Glasgow, UK) supplemented with 10% heat-inactivated fetal
bovine serum. β-HIVS was isolated from the plant L. radix as described
previously and dissolved in ethanol [10]. Phosphoproteins were fractionatedwith
a PhosphoProtein Purification kit (QIAGEN Inc., Darmstadt, Germany).
Polyclonal dUTPase-specific antibodies were kindly provided by Dr. Robert
D. Landner of the University ofMedicine andDentistry of New Jersey, USA. The
equipment for 2D-PAGE, Multiphor II, and Dry Gel Strips (pH 4–7) were
purchased fromAmersham Sciences (Piscataway, NJ, USA). HPLC-grade water,
formic acid, and acetonitrile were from Wako Pure Chemicals Industries, Ltd.
(Osaka, Japan). Proteomics grade trypsin was obtained from Promega (Madison,
WI, USA). 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS) and olomoucin were purchased from Sigma (St Louis, MO, USA).
2.2. Preparation of phosphoprotein
Phosphoproteins were enriched with the PhosphoProtein Purification kit
[20]. In brief, DMS114 cells were washed with 20 mM TBS buffer (20 mM
Tris–HCl, pH 7.6, 0.15 M NaCl) and lysed with phosphoprotein lysis buffer that
contained 0.25% CHAPS, benzonase and protease inhibitors (QIAGEN Inc.,
Darmstadt, Germany). After incubation for 30 min at 4 °C, samples were
centrifuged at 13,000 g at 4 °C for 30 min. Then 2.5 mg of protein in the lysate
were applied on phosphoprotein-purification column. The flow-through fraction
was collected and then, after the column had been washed with lysis buffer that
contained 0.25% CHAPS, 500 μl of phosphoprotein-elution buffer, containing
0.25% CHAPS, was applied and the eluate was collected. Each sample was
desalted with the VIVAspin system (Sartorius, Hannover, Germany) and a 2-D
Clean-Up Kit (Amersham Biosciences Corp., Piscataway, NJ, USA).
2.3. High-resolution two-dimensional gel electrophoresis
Proteins were separated, according to the manufacturer's instructions, on an
immobilized pH gradient-based isoelectric dry gel in the first dimension and by
SDS-PAGE in the second dimension. We applied 200 μg of protein to each 7-cm
isoelectric dry gel overnight, and then the gel was allowed to equilibrate in
50 mM Tris–HCl buffer (pH 8.8) that contained 6 M urea, 30% glycerol, 2%
SDS, and a trace of bromophenol blue. Electrophoresis of the first dimension was
conducted according to the manufacturer's instructions. Electrophoresis in the
second dimensionwas conducted in a slab gel that contained 12%acrylamide and
0.1% SDS in Laemmli's buffer system [21]. The proteins were detected by silver
staining. Image analysis and databasemanagement were performedwithMelanie
3 image-analysis software from GeneBio (Geneva, Switzerland).
2.4. In-gel reduction, alkylation, and digestion of proteins
For preparation of samples for analysis by micro-mass (micro-MS)
spectrometry, the silver-stained spots of protein were cut from the gel, washed
in water, immersed in acetonitrile, and dried with a centrifuge-concentrator
(TOMY SEIKO Co. Ltd., Tokyo, Japan). Dried fragments of the gel were
reduced by heating at 56 °C for 30 min in 100 mM dithiothreitol (DTT) that
contained 100 mM NH4HCO3, and alkylated by incubation at 37 °C for 30 min
in darkness with 100 mM iodoacetamide in 100 mM NH4HCO3. The fragments
of gel were then washed in 100 mM NH4HCO3, incubated in acetonitrile and
dried in the centrifuge-concentrator. Then each fragment was rehydrated for
45 min on ice in a solution of 1.25 μg of sequencing-grade trypsin (Promega,
Madison, WI) in 5 μl of 10 mM Tris–HCl (pH 8.8). Each sample was digested
at 37 °C overnight. Then each supernatant was removed and collected in a
fresh tube. Each fragment was then extracted twice with 5% formic acid in
50% acetonitrile. All supernatants from a given fragment were combined and
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sample was mixed with 0.1% trifluoroacetic acid and applied to a ZipTipC18
column (Millipore, Billerica, MA, USA). After the columns had been washed
with 0.1% trifluoroacetic acid, the sample was eluted with 75% acetonitrile.
Then the acetonitrile was removed with the centrifuge-concentrator.
2.5. Immunoblotting analysis
After samples had been prepared with the PhosphoProtein Purification kit,
they were fractionated by SDS-PAGE and transferred to a nitrocellulose
membrane. The membrane was rinsed with TBST [20 mM Tris (pH 7.4), 0.15 M
NaCl, 0.05% Tween 20] and then blocked with 5% skim milk in TBST for 1 h at
room temperature. The blocked membrane was subsequently probed for 1 h at
room temperature with diluted (1:1000) polyclonal antibodies against dUTPase.
After the membrane had been washed three times with TBST, it was incubated
for 1 h with horseradish peroxidase-conjugated goat antibodies against rabbit
IgG. Bands of immunoreactive proteins were detected with an ECL Kit
(PerkinElmer Life Sciences, Inc., Boston, MA, USA).
2.6. Detection of the induction of apoptosis
Apoptotic cells were detected by staining of cells with Hoechst 33342
(Sigma, St. Louis, MO, USA). Hoechst 33342-staining was conducted at room
temperature after treatment of cells with β-HIVS. Triplicate samples of a
minimum of 200 cells each were counted under fluorescence microscope
(BXSO; Olympus, Tokyo, Japan) and apoptotic cells were identified as cells
with condensed and fragmented nuclei as described previously [22]. Apoptosis
was also evaluated by measuring the formation of mono- and oligonucleosomes
using Cell-Death detection ELISAPLUS kit (Boehringer Mannheim, Mannheim,
Germany) in accordance with the manufacturer's instructions. The fragmenta-
tion of nucleosomes released into the cytosolic fraction was expressed in terms
of the difference in absorption at 405 nm and 495 nm.
2.7. Quantification of cell proliferation
Cell proliferation was quantified in terms of absorbance at 492 nm after
exposure of cells to 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-
5-carboxanilide (XTT). In brief, DMS114 cells (104 cells in 100 μl of medium
per well) were treated with β-HIVS for 24 h. After treatment, 50 μl of a solution
of XTT (1 mg/ml) and phenazine methosulfate (PMS; 0.383 mg/ml) were added.
Culture was continued for a further 4 h and then absorbance was measured at
492 nm with a microplate reader (Toyo Soda Kogyo, Ltd., Tokyo, Japan).
2.8. dUTPase-specific siRNA preparation and introduction into cells
siRNA that corresponded to part of the sequence of dUTPase mRNA was
designed with a 5′ phosphate, a 3′ hydroxyl group, and a two-base overhang
(TT) at the 3′ end of each strand was synthesized by QIAGEN Inc. The
following sequences were used to target dUTPase mRNA: sense strand, 5′-
AGGUGAUCGAAUUGCACCAGd(TT)-3′; and antisense strand, 5′-d(TT)
UCCACUAGCUUAACGUGUC-3′ (nucleotides 404–424; Genbank accession
no. BC033645). The sequence of non-silencing strands is as follows: sense
strand, 5′-UUCUCCGAACGUGUCACGUd(TT)-3′; antisense stand, 5′-
ACGUGACACGUUCGGAGAAd(TT)-3′. Complementary strands were
annealed by incubation at 90 °C for 1 min and then at 37 °C for 1 h.
DMS114 cells were incubated for 24 h in RPMI 1640 supplemented with 10%
fetal calf serum, and then they were treated with 5 μg of the siRNA in the same
culture medium in the presence of RNAiFect transfection reagent (QIAGEN
Inc.). After incubation for 48 h, the incubation medium was replaced by fresh
RPMI 1640 supplemented with 10% fetal calf serum and then the cells were
treated with β-HIVS for 24 h prior to assays.
2.9. Mass-spectrometric analysis and identification of peptides
Peptide mass analysis was performed on a Q-TOF micro-mass spectrometer
(Waters, Manchester, United Kingdom). Data were acquired and processed withMassLynx version 4.0 (Nihon Waters, K. K., Tokyo, Japan). Data were
submitted to the SWISS-PROT and MSDB databases using MASCOT
(MATRIX SCIENCE, Boston, MA, USA) as the search engine and ion scores
calculated by MASCOT data base software are used to evaluate the probability
of the identification of the peptides [23].
2.10. Measurement of dUTPase activity
dUTPase activity was measured using a slight modification of the method
described by Williams et al. [24,25]. After treatment of DMS114 cells with
β-HIVS, cells were lysed with phosphoprotein lysis buffer, as described above.
The reaction was allowed to proceed at 37 °C for 10 min using cell lysate that
contained 5 μg of protein in a total volume of 100 μl of 50 mM Tris–HCl (pH
7.5) that contained 4 mMMgCl2, 2 mM β-mercaptoethanol, 0.1% bovine serum
albumin, 25 mM NaF, 0.1 mM [5-3H]dUTP (100 μCi/μmol). After the reaction
was stopped by heating at 100 °C for 3 min, 20 μl of a mixture of dUTP and
dUMP (100 mM each) was added and the reaction mixture was centrifuged at
7700 ×g for 5 min. Ten μl of the resultant supernatant thus obtained were spotted
on a Polygram CEL 300 PEI/UV254 plate (Machery-Nagel, Eaton, PA, USA).
The plate was developed with 0.5 M LiCl in 2 N acetic acid. The spot
corresponding to dUMP was scraped off from the plate and radioactivity was
measured in a liquid scintillation counter.3. Results
3.1. Analysis of fluctuations in levels of proteins during
β-HIVS-induced apoptosis in DMS114 cells
As reported previously [22], β-HIVS induces apoptosis in
human lung cancer DMS114 cells. Namely, treatment of
DMS114 cells with β-HIVS caused release of cytochrome c
from mitochondria, cleavage and fragmentation of DNA, and
condensation and fragmentation of nuclei [22]. When DMS114
cells were treated with 5 μM β-HIVS and then stained with
Hoechst 33342, approximately 35% of the cells displayed
morphological changes characteristic of apoptosis, such as
condensed and fragmented nuclei (data not shown). To identify
proteins that might play important roles in the signal
transduction pathways in β-HIVS-induced apoptosis in
DMS114 cells, we analyzed phosphoprotein fraction by 2D-
PAGE after fractionation of cell lysates on a phosphoprotein-
purification column. After DMS114 cells had been treated with
5 μM β-HIVS for 24 h, the cells were lysed and the lysate was
applied to the phosphoprotein-purification column. Phospho-
protein fraction was eluted as described in Materials and
methods. Fig. 1B shows typical 2D profiles of eluates derived
from DMS114 cells that had been treated with or without
β-HIVS. We observed that the intensity of a spot in the phos-
phoprotein fraction, which had been eluted from the phospho-
protein-purification column, (indicated by the red arrows in
Fig. 1B) was reproducibly reduced by treatment of cells with
β-HIVS. By contrast, the intensity of the spot due to a well-
known phosphoprotein, stathmin [26], indicated by the blue
arrows in Fig. 1B, was unchanged by treatment of DMS114
cells with β-HIVS. Using the spot of stathmin as a landmark,
we estimated that intensity of the spot indicated by the red
arrows had decreased by more than 50%. Under our expe-
rimental conditions, we failed to detect any proteins fluctuated
reproducibly by the β-HIVS treatment in the flow-through
fraction from the lysate (Fig. 1C). As shown in Fig. 1A, a spot
Fig. 2. Identification of dUTPase by mass spectrometry and Western blotting
analysis. A, Amino acid sequences of peptides obtained from the spots indicated
by a red arrow in Fig. 1B, as determined by micro-mass spectroscopy and
described in the text. B, The amino acid sequence of dUTPase. The underlined
sequences correspond to those of peptides identified by mass spectrometry. Ion
scores calculated by MASCOT data base software were used to identify the
peptides as described in the text.Multiplematched peptides with ions scores above
40 as well as the resulting total ions score above 100 are sufficient for protein
identification [23]. C,Western blotting analysis with polyclonal antibodies against
dUTPase. DMS114 cells were treated with 5 μM β-HIVS for 24 h and then lysed.
The lysate was fractionated on a phosphoprotein-purification column as described
in the text and each fraction containing 5 μg of protein was used for SDS-PAGE.
The result shown is typical of three experiments that gave similar results.
Fig. 1. Mapping of phosphoprotein and nonphosphoprotein fractions of lysates of DMS114 cells treated with β-HIVS. After DMS114 cells that had been cultured with
or without 5 μM β-HIVS for 24 h, the cells were washed with TBS buffer and lysed with lysis buffer that contained 0.25% CHAPS. The lysate was applied to a
phosphoprotein-purification column and phosphoprotein and nonphosphoprotein fractions were obtained fractionated as described in the text. After desalting, the total
lysate (A), the eluate fraction (B) and flow-through fraction (C) (200 μg of protein each) were fractionated 2D-PAGE and then the gels were stained with silver.
Stathmin, indicated by blue arrowheads, was utilized as a landmark protein for comparisons of the intensities of spots of dUTPase. The red arrowheads indicate the
spots of dUTPase in the eluate fractions. Areas corresponding to dUTPase in the lysate fraction were circled and indicated also by the red arrowheads.
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detected by silver staining (the red arrows indicate positions of
the absent spot of dUTPase). These results indicated that the
phosphoprotein-purification column concentrated the dUTPase.
We cut out the spot indicated by the red arrow in Fig. 1B
from the gel and digested the material with trypsin after
reduction with DTT and alkylation with iodoacetoamide, as
described in Materials and methods. After tryptic digestion, we
extracted peptides with 50% acetonitrile that contained 5%
formic acid and analyzed them by mass spectrometry. As shown
in Fig. 2A and B, the peptide sequences that we determined
matched three partial amino acid sequences of dUTPase, which
is known to be a phosphorylated protein [18].
To confirm that the level of phosphorylated dUTPase in
DMS114 cells was reduced by treatment of cells with β-HIVS,
we immunoblotted the proteins in the lysate as well as in the
eluate and flow-through fractions obtained from the phospho-
protein-purification column (Fig. 2C). The intensity of the band
due to dUTPase in the lysate was faint but decreased by
approximately 16% upon the treatment with β-HIVS, as
estimated by densitometric scanning of the Western blotting
bands. As is evident from Fig. 2C, the band of dUTPase in the
phosphoprotein fraction was markedly reduced after treatment
of cells with β-HIVS. No band due to dUTPase in the flow-
through fraction was detected.
To validate the above suggestion, we introduced siRNA
directed against dUTPase mRNA into DMS114 cells. The
nucleotide sequence of dUTPase-specific siRNA used in the
present study was different from those used previously [27,28].
As shown in Fig. 3A, this siRNA caused a marked decrease in
the level of dUTPase itself, as determined by immunoblotting.
The expression of TRAP1, which is another molecule that
transmits the signal that originates upon exposure of cells to β-
HIVS [22], was unaffected by transfection with siRNA againstdUTPase (Fig. 3A). Therefore, we used DMS114 cells that
contained the siRNA against dUTPase mRNA in a series of
experiments in which we examined the effects of the treatment
Fig. 3. Effects of transfection of siRNA against dUTPase on DMS114 cells.
siRNA against dUTPase mRNA or non-silencing siRNA was introduced into
DMS114 cells using RNAiFect reagent, as described in the text. A, Western
blotting analysis of lysates of DMS114 cells, as indicated. B, After incubation for
48 h in medium that contained the siRNA against dUTPase mRNA and
RNAiFect reagent, the medium was replaced by RPMI 1640 supplemented with
10% fetal calf serum and cells were treated withβ-HIVS for 24 h. Apoptotic cells
were identified by staining with Hoechst 33342 and counted. Asterisks indicate
that the values are statistically significantly different (⁎pb0.01; ⁎⁎pb0.0002).
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Fig. 3B, dUTPase-specific siRNA-harboring DMS114 cells
exhibited slight but significant increase in the extent of
induction of apoptosis as compared with that induced by non-
silencing siRNA. Neither treatment with RNAiFect alone nor
treatment with a control non-silencing siRNA caused any
significant increase in the percentage of apoptotic cells. The
effect of β-HIVS on the specific siRNA-transfected cells with
2.5 μM β-HIVS resulted in the markedly enhanced induction of
apoptosis, as compared with its effect on the cells that harbored
the non-silencing control siRNA (Fig. 3B). These results
indicated that DMS114 cells became more sensitive to β-HIVS
upon the introduction of siRNA directed against dUTPase
mRNA.
3.2. Effects of β-HIVS on dUTPase activity
Since the level of dUTPase in the phosphoprotein fraction
from DMS114 cells was reduced by treatment of cells with
β-HIVS, we examined whether the activity of dUTPase might
also be changed upon treatment of cells with β-HIVS. As
shown in Fig. 4A, the percentage of apoptotic cells, as de-termined by Hoechst 33258-staining under the fluorescent mic-
roscope, was increased by treatment with β-HIVS in a dose-
dependent manner. Apoptosis was also evaluated by measuring
of mono- and oligonucleosomes released into the cytosolic
fraction (Fig. 4A). The number of fragmented nucleosomes also
increased with increasing concentrations of β-HIVS in parallel
with the percentage of apoptotic cells, as determined micro-
scopically in terms of chromatin condensation and nuclear
fragmentation. In parallel with the increase in the induction of
apoptosis in DMS114 cells by β-HIVS, dUTPase activity in the
cells decreased upon treatment of cells with β-HIVS and the
effect was dose-dependent (Fig. 4B). As shown in Fig. 4C,
the induction of apoptosis in DMS114 cells began within 1 h of
the start of treatment with 2.5 μM β-HIVS. dUTPase activity
fell by 44% from the control value within 0.5 h after the start of
treatment of DMS114 cells with 2.5 μM β-HIVS (Fig. 4D),
suggesting that a decrease in dUTPase activity might trigger the
induction of apoptosis in DMS114 cells. The time course
changes in amounts of phosphorylated dUTPase in lysates of
DMS114 cells that had been treated with β-HIVS were
estimated using the phosphoprotein-purification column, as
described in Materials and methods. The results of Western
blotting (Fig. 4E) showed clearly that the level of phosphory-
lated dUTPase eluted from the phosphoprotein-purification
column fell sharply 0.5 h after the start of treatment with
β-HIVS. The decreased level of phosphorylated dUTPase
0.5 h after the treatment with β-HIVS was approximately
63% as estimated by densitometric scanning of the Western
blotting bands of Fig. 4E. These results suggested that the
reduction of dUTPase activity in DMS114 cells by β-HIVS
might be caused by the decrease in the level of the phospho-
rylated form of this enzyme.
3.3. Effects of olomoucin on the induction of apoptosis and on
the level of dUTPase in DMS114 cells
Since nuclear dUTPase is phosphorylated by the phosphory-
lated cyclin–cdc2 complex [18], we examined the effect of
olomoucin, an inhibitor of cdc2 [29,30], on the induction of
apoptosis and the phosphorylation of dUTPase in DMS114 cells.
As shown in Fig. 5A, apoptosis was sharply induced in DMS114
cells by treatment with 100 μM olomoucin for 24 h. By the
incubation of DMS114 cells with olomoucin for 24 h, the level
of dUTPase in the phosphoprotein fraction prepared from the
olomoucin-treated cells was markedly reduced (Fig. 5B). These
results suggested that inhibition of cdc2 by olomoucin leads to
decrease in the level of phosphorylated dUTPase. U0126
(10 μM), SP600125 (10 μM), and SB203580 (20 μM), which
are inhibitors for ERK, JNK, and p38-MAP kinases, respec-
tively, did not show any effect on the level of dUTPase in the
phosphoprotein fraction of DMS114 cells (results not shown).
3.4. Inhibition of β-HIVS-induced suppression of the expression
of dUTPase by antioxidant
We previously demonstrated that the induction of apoptosis
in DMS114 cells by β-HIVS was inhibited by N-acetyl-
Fig. 4. Effects of treatment of DMS114 cells with β-HIVS on the activity of dUTPase. A, Effects of various concentrations of β-HIVS on the induction of apoptosis in
DMS114 cells. DMS114 cells were treatedwith various concentrations ofβ-HIVS for 24 h and percentages of apoptotic cells (●) and the fragmentation of nucleosomes (○)
were determined as described in the Materials and methods. Apoptotic cells (%) were analyzed by staining with Hoechst 33342 and counted as described in the legend to
Fig. 3. The fragmentation of DNAwas determined bymeasuring nucleosomes released into the cytosolic fraction using Cell-Death detection ELISAPLUS kit and expressed
in terms of the difference in absorption at 405 nm and 495 nm. B, Effects of treatment of DMS114 cells with various concentrations ofβ-HIVS on dUTPase activity in cells.
AfterDMS114 cells had been treatedwith various concentrations ofβ-HIVS for 24 h, dUTPase activitywasmeasured as described in the text. C,Dependence on time of the
induction of apoptosis during treatment of DMS114 cells with β-HIVS. After DMS114 cells had been treated with 5 μM β-HIVS for various times, apoptotic cells were
counted as described above. D, Effects of treatment with β-HIVS on dUTPase activity in DMS114 cells. dUTPase activity was measured after treatment of DMS114 cells
with 5 μMβ-HIVS for various times. E,Western blotting analysis of dUTPase in the phosphoprotein fraction of lysates of DMS114 cells that had been treated withβ-HIVS
for various times. Western blotting analysis of phosphoprotein fractions was performed as described in the legend to Fig. 2.
Fig. 5. Effects of olomoucin on the induction of apoptosis and on the level of
dUTPase in DMS114 cells. A, After DMS114 cells had been treated with
100 μM olomoucin for 24 h, the extent of induction of apoptosis was measured
as described in the legend to Fig. 4. B, Effects of olomoucin on the amount of
dUTPase. After DMS114 cells had been treated with 100 μM olomoucin for
24 h, level of dUTPase in the phosphoprotein fraction were determined by
Western blotting as described in the legend to Fig. 2.
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reactive oxygen species (ROS), suggesting the involvement of
ROS in the induction of apoptosis by β-HIVS [22]. In
addition, the decrease in levels of TRAP1 upon treatment of
DMS114 cells with β-HIVS was inhibited by NAC, suggest-
ing the involvement of ROS in the regulation of the
expression of TRAP1 in mitochondria [22]. Therefore, we
examined the effect of NAC on suppression of the level of
dUTPase in response to β-HIVS. Although the band due to
dUTPase in the lysate obtained from untreated DMS114 cells
was faint, its intensity was reduced by 20% upon treatment
with β-HIVS as quantified by the densitometry and this
reduction was inhibited by the presence of NAC (Fig. 6). The
band of dUTPase in the eluate fraction obtained from the
lysate of DMS114 cells by the phosphoprotein-purification
column was also clearly and markedly reduced by treatment
with β-HIVS and again the suppression of the level of
dUTPase by β-HIVS was inhibited in the presence of NAC.
This observation suggests that the level of dUTPase might be
regulated by ROS formed as a result of treatment of DMS114
cells with β-HIVS.
Fig. 6. Inhibition of β-HIVS-induced suppression of the expression of dUTPase
by N-acetyl-cysteine (NAC). After DMS114 cells were treated with 5 μM
β-HIVS for 24 h in the presence or absence of 1 mM NAC, the cells were lysed
as described in Fig. 1. Each lysate was fractionated on a phosphoprotein-
purification column as shown in Fig. 2. Each fraction was analyzed by SDS-
PAGE and subsequent immunoblotting as described in the legend to Fig. 2. The
result shown is typical of three experiments that gave similar results.
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The effects of various apoptosis-inducing anticancer agents
on the level and activity of dUTPase in DMS114 cells wereFig. 7. Effects of various anticancer agents on the induction of apoptosis and
dUTPase in DMS114 cells. DMS114 cells were treated with 2.5 μM β-HIVS,
50 μM cisplatin, 1 μM camptothecin (CPT), or 100 μM VP16 for 24 h. A,
Induction of apoptosis in DMS114 cells was measured as described in the legend
to Fig. 2. B, Effects on dUTPase activity, which wasmeasured as described in the
legend to Fig. 4. C, Western blotting analysis of dUTPase in the phosphoprotein
fraction of lysates of DMS114 cells that had been treated with various anticancer
agents. Cell lysates were prepared and phosphoprotein fractions were obtained as
described in the legend to Fig. 1. Western blotting analysis of the phosphoprotein
fractions was performed as described in the legend to Fig. 2.examined. The cells were treated with 2.5 μM β-HIVS, 50 μM
cisplatin, 1 μM camptothecin, or 100 μM VP16 (etoposide) for
24 h. Under these conditions, apoptosis was induced in more
than 30% of the cells by each drug (Fig. 7A). However, a
marked decrease in dUTPase activity was observed only in
DMS114 cells treated with β-HIVS (Fig. 7B). Reflecting with
this result, a marked decrease in the level of dUTPase in the
phosphoprotein fraction of DMS114 cells occurred only when
the cells had been treated with β-HIVS (Fig. 7C).
3.6. Synergistic effects of β-HIVS and 5-FU on the inhibition of
growth of DMS114 cells
Since an increase in the expression of dUTPase in human
lung and ovarian tumor cell lines is known to result in resistance
to 5-fluorouracil (5-FU), which is an inhibitor of thymidylate
synthase and is widely used as an anticancer drug [31], we
examined whether the decrease in dUTPase activity in DMS114
cells that was caused by treatment with β-HIVS might change
the sensitivity of the cells to 5-FU. As shown in Fig. 8, growth
of DMS114 cells was inhibited markedly by as little as 1 μM
β-HIVS. By contrast, DMS114 cells were not very sensitive to
5-FU, and treatment with 250 μM 5-FU inhibited growth of
DMS114 cells by only approximately 20% (Fig. 8). Although
treatment of DMS114 cells with 0.5 μM β-HIVS had no
significant inhibitory effect on cell growth, 0.5 μM β-HIVS in
combination with either 100 μM or 250 μM 5-FU had a marked
synergistic inhibitory effect on cell growth. A synergistic inhi-
bitory effect on the growth of DMS114 cells was also observed
after treatment of DMS114 cells with either 1 μM β-HIVS or
2 μM β-HIVS combined with 5-FU at either 100 μMor 250 μM
(Fig. 8).Fig. 8. Synergistic inhibitory effects of β-HIVS and 5FU on the growth of
DMS114 cells. DMS114 cells were treated for 24 h with various concentrations
of either β-HIVS or 5FU alone, and of the two drugs in combination. Cell
growth was quantified by the XTT assay, as described in the text. The results
shown are means+SD (bars) of the results obtained from triplicate samples.
Three experiments were performed and the results were producible.
Fig. 9. Schematic representation of the effect of β-HIVS on dUTPase in
DMS114 cells. The inhibition of unknown tyrosine kinase(s) by β-HIVS results
in the induction of ROS. NAC, a scavenger of ROS, efficiently inhibited the
β-HIVS-induced suppression of dUTPase as well as induction of apoptosis. The
expression and activity of PLK1 is also decreased via inhibition of unknown
tyrosine kinase(s) by β-HIVS [15]. Phosphorylation of cyclin B1 in the cyclin
B1–cdc2 complex by PLK1 is required for translocation of the complex to the
nucleus [35] and the phosphorylated cyclin B1–cdc2 complex phosphorylates
dUTPase in the nucleus [18]. Treatment of DMS114 cells with olomoucin, an
inhibitor of cdc2, inhibited the phosphorylation of dUTPase leading to its
decrease in the phosphoprotein fraction. Combined treatment of DMS114 cells
with β-HIVS and 5-FU, a specific inhibitor of thymidylate synthase, induced a
synergistic growth-inhibitory effect. White arrows indicate changes induced by
treatment of DMS114 cells with β-HIVS. The broken lines indicate unknown
mechanisms.
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A protein tyrosine kinase inhibitor, β-HIVS, is a potent
inducer of apoptosis against lung cancer cells. To analyze the
mechanism for β-HIVS-induced apoptosis, we have carried out
proteomic analysis of phosphorylated proteins to analyze the
changes in phosphoprotein profiles with or without β-HIVS
treatment. We found one protein that reduced markedly after
β-HIVS treatment, and this protein was identified as dUTPase.
dUTPase is a ubiquitous enzyme that hydrolyzes dUTP to
yield dUMP which is then converted to dTMP by thymidilate
synthase. Thymidylate synthase is an important step of
nucleotide synthesis, and accumulation of dUTP by inhibition
of thymidilate synthase leads to misincorporation of uracil into
DNA and results in lethal damage to DNA [5]. Recently,
increasing evidences were independently presented to suggest
that dUTPase is associated with induction of apoptosis,
although the mechanism of its association with apoptosis is
not resolved [32–34]. In agreement with our results, dUTPase
was identified in 12 proteins that their levels were decreased
during induction of apoptosis in human Burkitt lymphoma cell
line by treatment with anti-IgM antibody [32]. Down regulation
of dUTPase in colon cancer HCT116 cells was also observed
during apoptosis by treatment with resveratol, which is a
polyphenol found in red wine [34]. dUTPase in human amnion
epithelial cells was also decreased by treatment with N-methyl-
N′-nitro-N-nitrosoguanidine, which is a N-nitroso alkylating
carcinogen [33].
We found in the present study that approximately 44% of the
dUTPase activity was lost within 0.5 h after the treatment of
DMS114 cells with 2.5 μM β-HIVS. This decrease in dUTPase
activity in DMS114 cells corresponds to the decrease in the
level of dUTPase in the phosphoprotein fraction, which also
occurred within 0.5 h of the start of treatment with β-HIVS. In
addition, the dUTPase activity in the cells was decreased by
β-HIVS in a dose-dependent manner, and the extent of the
induction of apoptosis was similarly increased with greater
concentrations of β-HIVS.
To prove further the involvement of dUTPase in the β-HIVS-
inducted apoptosis, siRNA directed against dUTPase mRNA
was introduced into DMS114 cells. When the expression of
dUTPase protein was strongly inhibited, the extent of induc-
tion of apoptosis was significantly increased. Furthermore,
treatment of dUTPase-specific siRNA-containing cells with
β-HIVS showed a synergistic effect on induction of apo-
ptosis, while non-silencing RNA did not enhance β-HIVS-
induced apoptosis. From these results, it is suggested that
dUTPase activity is directly involved in apoptosis in DMS114
cells. In addition, it is possible that the suppression of dUTPase
activity in the cells may increase susceptibility to β-HIVS-
induced apoptosis.
Ladner et al. demonstrated that the phosphorylated Ser11 in
dUTPase is located within a context that corresponds to the
consensus target sequence of the cyclin-dependent protein
kinase cdc2 [18]. dUTPase is indeed phosphorylated by the
cyclin B1–cdc2 complex [18]. Phosphorylation of cyclin B1 at
the position Ser147 by polo-like kinase 1 (PLK1) leads to thecyclin B1–cdc2 complex formation [35]. The association of
cdc2 with cyclin B1 and the phosphorylation of cyclin B1 by
PLK1 are required for the translocation of the cyclin B1–cdc2
complex to the nucleus [36]. Apoptosis was induced via
suppression of the of PLK1 kinase activity after inhibition of
PTK activity in leukemia HL60 and U937 cells by β-HIVS
[15]. We also demonstrated in the present study that the level of
phosphorylated dUTPase in DMS114 cells decreased by
treatment with olomoucin, an inhibitor of cdc2, and this treat-
ment induced apoptosis.
A previous report demonstrated that ROS produced upon
inhibition of PTK by β-HIVS caused a decrease in levels of
TRAP1 in mitochondria and a resultant release of cytochrome c
from the mitochondria [22]. In the present study, NAC, a sca-
venger of ROS, efficiently inhibited both the suppression of the
level of dUTPase and induction of apoptosis induced by
treatment of DMS114 cells with β-HIVS. These results
suggested that ROS produced through inhibition of unknown
PTK by β-HIVS might be located upstream of the apoptosis-
inducing signaling pathways (Fig. 9). The two signaling path-
ways, one dependent on mitochondria and the other through
phosphorylated dUTPase, might cooperate to induce efficient
apoptosis in DMS114 cells in response to β-HIVS (Fig. 9).
5-Fluorouracil is a specific inhibitor of thymidylate synthase
and is one of the most widely used chemotherapeutic drugs for
the treatment of head and neck, breast, and gastrointestinal
cancers [31]. However, successful treatment with 5-FU is often
hampered by the development of resistance to this drug. Ladner
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cancer strongly correlated with resistance to 5-FU therapy [6].
In addition, increased expression of dUTPase in human lung
H1299 and ovarian SK-OV-3 carcinoma cell lines resulted in
significant resistance to 5FU [7]. Thus, a decrease in the level of
dUTPase might contribute to an increase in sensitivity of cancer
cells to 5-FU. Koehler and Ladner demonstrated that siRNA
directed against dUTPase suppressed the expression of this
enzyme and sensitized cancer cell lines to growth inhibition by
the thymidylate synthase inhibitor fluorodeoxyuridine [27]. The
present study demonstrated a significant synergistic inhibitory
effect on cell growth when DMS114 cells were treated with
5-FU and β-HIVS together. It is interesting to point out that
treatment of lung cancer with 5-FU and β-HIVS simultaneously
might have a good therapeutic potential.
We have previously demonstrated that treatment of DMS114
cells with cisplatin and β-HIVS together synergistically
inhibited cell growth and induced apoptosis [12]. Although
the antitumor effect of cisplatin is believed to be due to the
formation of covalent adducts with DNA [37,38], cisplatin also
reacts with the sulfhydryl groups of cysteine residues in proteins
[37]. We found that tyrosine kinase activities in DMS114 cells
were synergistically inhibited by the combined treatment with
β-HIVS and cisplatin, and concluded that the synergistic effects
observed for DMS114 cells might be due to inhibition of a
tyrosine kinase-dependent pathway [12].
In conclusion, the present study demonstrates a new way to
increase the sensitivity of lung cancer DMS114 cells to 5-FU
using β-HIVS. Our observations suggest the potential clinical
utility of combined treatment with inhibitors of tyrosine kinases
and thymidylate synthase.
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